KUALA LUMPUR, Nov 14 (Reuters) - Canada has paused imports from Malaysian glove maker Supermax Corp as it awaits the results of an audit, weeks after the United States barred the firm over allegations the company uses forced labour.

Malaysian factories making everything from medical gloves to palm oil have increasingly come under scrutiny over allegations they abuse foreign workers, who form a significant part of the manufacturing workforce.

After the United States suspended Supermax imports last month, Canada's Public Services and Procurement department said on Wednesday it was holding Supermax deliveries as it awaits a report expected mid-month from Supermax Healthcare Canada.

"In light of the current situation, Canada has engaged with the company to seek assurances that Supermax Corp is not engaging in forced labour practices," the department said in a statement.

All gloves rebound today including Supermax up 6.9% getting closer to Supermax QR release within 1-2 weeks

With CBP ban and ASP downtrend until 1st quarter next year Supermax coming QR profits will be less than 500 millions per quarter

Due to CBP ban Supermax will be handicapped compares to Top Glove, Hartalega and Kossan

Supermax coming QR next 1-2 weeks and CBP ban are negative factors for further price uptrend

SD very soon being delisted by Bursa if not categorized as PN17 company

Looks very likely Hartalega share price will fall below RM5 after ex-date next Wednesday followed by much anticipated Supermax QR release 1 week later

Shares keep falling until pre pandemic price below RM1 before rebound after ASP normalized 1st quarter next year

Glove capacity utilisation already slow down from 90+% to 60+% due to capacity expansion and slower demand

KUALA LUMPUR (Nov 11): Supermax Healthcare Canada Inc (SHC) is undertaking an independent auditing process of the working conditions at its facilities in place.

In a statement on Wednesday (Nov 10), SHC said the audit was being conducted by an independent firm specialising in compliance with International Labour Organization (ILO) criteria after the US Customs and Border Protection (CBP) issued a Withhold Release Order (WRO) against the company and its subsidiaries' products on forced labour allegations.

Back to pre pandemic price below RM1 soon until ASP normalized 1st quarter next year

Bursa and SC will delist this rubbish company soon and luckily EPF already not substantial shareholder anymore

Serba Dinamik soon will be delisted and kick out from listing in Bursa pity all shareholders

Waiting for Supermax QR release coming soon this month but profits should drop at least 50% similar to Hartalega and Kossan

All waiting for Supermax QR release coming soon this month profits should drop 50%-60% similar to Hartalega and Kossan

Minor rebound for Supermax 1.73 but Top Glove and Kossan closing new low 2.30 and 2.13

Top Glove 2.30 vs Kossan 2.13 vs Supermax 1.75 downtrend continues awaiting Supermax QR release coming 1-2 weeks

Minor rebound for Supermax after heavy sell off yesterday

Comfort high selling pressure breaks 1.10 and going to drop back below RM1 before pandemic

Comfort share price going to break 1.10 and heavy losses for those buying few months back

Top Glove closing new low today but short selling volume today 31k shares only out of total daily transaction 14 millions shares today equivalent to just 0.2% RSS volume....High selling today must be from local and foreign institutional investors

Supermax heavy selling down today 7% but short selling volume today 28k shares only out of total daily transaction 16.5 millions shares today equivalent to just 0.17% RSS volume.... High selling today must be from local and foreign institutional investors

Supermax closing new low 1.71 falling 7% today very terrible capital loss as share prices will keep downtrend as it nears QR release end of this month

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck’s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight.

Pfizer CEO Albert Bourla told CNBC the company plans to submit its data to the Food and Drug Administration before Thanksgiving.

“I think this medicine will change the way things are happening right now that will save millions and millions of lives, it has the potential to do it,” Bourla said in an interview on CNBC’s “Squawk Box.” He said the company has “the capacity right now of 500 million pills,” which he said translates to 50 million treatments. “The very high efficacy comes even to us as a surprise, exceeds our most visionary expectations we had for that.”

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck’s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight.

Pfizer CEO Albert Bourla told CNBC the company plans to submit its data to the Food and Drug Administration before Thanksgiving.

“I think this medicine will change the way things are happening right now that will save millions and millions of lives, it has the potential to do it,” Bourla said in an interview on CNBC’s “Squawk Box.” He said the company has “the capacity right now of 500 million pills,” which he said translates to 50 million treatments. “The very high efficacy comes even to us as a surprise, exceeds our most visionary expectations we had for that.”

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck’s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight.

Pfizer CEO Albert Bourla told CNBC the company plans to submit its data to the Food and Drug Administration before Thanksgiving.

“I think this medicine will change the way things are happening right now that will save millions and millions of lives, it has the potential to do it,” Bourla said in an interview on CNBC’s “Squawk Box.” He said the company has “the capacity right now of 500 million pills,” which he said translates to 50 million treatments. “The very high efficacy comes even to us as a surprise, exceeds our most visionary expectations we had for that.”

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck’s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight.

Pfizer CEO Albert Bourla told CNBC the company plans to submit its data to the Food and Drug Administration before Thanksgiving.

“I think this medicine will change the way things are happening right now that will save millions and millions of lives, it has the potential to do it,” Bourla said in an interview on CNBC’s “Squawk Box.” He said the company has “the capacity right now of 500 million pills,” which he said translates to 50 million treatments. “The very high efficacy comes even to us as a surprise, exceeds our most visionary expectations we had for that.”

Looks like lower and lower price every day if share price continues falling until QR release end of this month

Stoxxpixx2u and Wexxth Arcxxtech already inactive few months ago and set up new private group...Comfort next support should be 1.10 before moving closer to pre pandemic price 80-90 sen

Share price keeps falling as it moves closer to QR release

Supermax downtrend continues as selling pressure too strong and many bad news ASP drop,CBP ban and makmur tax 33%

Ular Sawa 81 sen is Singapore Top Glove...Lol

All waiting for Supermax QR tis month

Hoping Supermax to release QR by next week as Kossan and Hartalega QR already released last 1 week

Supermax rebound today closing green should release coming QR by next week rather than waiting end November

Top Glove share price 2.49 is closing in on Kossan share price 2.43 today

Supermax share buy back losses distribute to shareholders as treasury shares ratio 1:30 as announced end October

KUALA LUMPUR (Nov 3): Despite Hartalega Holdings Bhd reporting decent results in the second quarter ended Sept 30, 2021 (2QFY22), most analysts on Wednesday reduced their earnings forecasts on the company as they see the firm to be one of the few companies that will be hit the hardest by the proposed “Cukai Makmur” (prosperity tax), which is applicable for the year of assessment 2022.

According to analysts, Hartalega’s earnings for the financial year ending March 31, 2022 (FY22) will be hit hard by the additional one-off special windfall tax as the management estimated the additional tax bill at about RM400 million.

Citing management, they said the tax will materially impact the bottom line of Hartalega in the second half of FY22 (2HFY22), as the group’s year of tax assessment for 2022 falls during the period of April 1, 2021 to March 31, 2022, which is the most profitable period for most of the glove players.

KAF Research, which maintained its "sell" call and target price of RM4.79 for Hartalega, said the glove maker may be the worst impacted by the “prosperity tax” as compared to its closest peers, which saw earnings peak in FY21.

Maybank Investment Bank Research, which reiterated its "sell" call and target price of RM4 for Hartalega, also opined that Hartalega's 2HFY22 earnings performance will be weaker, no thanks to declining ASP and the additional tax charges arising from the prosperity tax.

Very painful experience for Top Glove investors except Ularsawa always renewing FD at higher interest rate

Top Glove under selling pressure with huge capital loss so big even renewing FD at higher interest rate also useless

New low for Top Glove under heavy selling pressure

Supermax director keep selling Supermax shares not a good indication really depressing share prices until QR release end of this month

Hartalega paying highest dividend payout among top 4 glove companies and has highest cash balances RM5 billions

Supermax coming QR profits end of this month will drop to RM500 millions or less expecting less dividend payout

Profit after tax RM914 millions but very high dividend 35 sen good for shareholders especially Kuan family with 50% shareholding

KUALA LUMPUR (Nov 1): A cumulative RM33.8 billion of value was wiped off the market capitalization of stocks on Bursa Malaysia on Monday in a knee-jerk reaction to the government’s one-off 'cukai makmur' (prosperity tax) proposal.

The major selloff saw the total value of the stocks come down to RM1.77 trillion from RM1.81 trillion last Friday.

The FBM KLCI, meanwhile, closed down 31.39 points or 2.01% to 1,530.92, its biggest one-day decline since March 31 when the US bond yield and dollar surged.

KUALA LUMPUR (Nov 1): A cumulative RM33.8 billion of value was wiped off the market capitalization of stocks on Bursa Malaysia on Monday in a knee-jerk reaction to the government’s one-off 'cukai makmur' (prosperity tax) proposal.

The major selloff saw the total value of the stocks come down to RM1.77 trillion from RM1.81 trillion last Friday.

The FBM KLCI, meanwhile, closed down 31.39 points or 2.01% to 1,530.92, its biggest one-day decline since March 31 when the US bond yield and dollar surged.

KUALA LUMPUR (Nov 1): A cumulative RM33.8 billion of value was wiped off the market capitalization of stocks on Bursa Malaysia on Monday in a knee-jerk reaction to the government’s one-off 'cukai makmur' (prosperity tax) proposal.

The major selloff saw the total value of the stocks come down to RM1.77 trillion from RM1.81 trillion last Friday.

The FBM KLCI, meanwhile, closed down 31.39 points or 2.01% to 1,530.92, its biggest one-day decline since March 31 when the US bond yield and dollar surged.

All waiting for Hartalega QR this week

Bursa stocks almost all red tsunami drops more than 30 points and Supermax shares falling to new lows as expected